Outcomes-based pricing for Cardiovascular Disease

An interest Health Affairs blog post on outcomes-based pricing from Daniel M. Blumenthal Samuel Nussbaum Neil J. Weissman and Mark Linthicum. Insurers are increasingly tying health service payments to clinical outcomes to improve care value and quality. Outcomes-based pricing—setting treatment reimbursements to reflect their prospectively determined value to patients and the health care system—is a promising alternative payment…

What is more for cancer patients: increased screening or treatment innovation?

Let’s get this out of the way: both are clearly important.  Within appropriate screening, patients don’t get the treatment they need.  Further, delayed screening can make treatments less effective if the cancer has progressed or metastasized.  On the other hand, without effective treatment, screening won’t have a major impact on patient outcomes. The question is,…

What does “value” really mean?

An interesting article in Stat makes the important point that although there is much talk about “value” in the media and health policy world, the exact definition of “value” depends on your presepective. But a survey released Wednesday by the University of Utah shows that, in health care, value has no universal meaning — 88 percent of doctors…

Off-label prescribing

How frequently are pharmaceuticals used off label?  Perhaps more than you think.  Although these figures are a bit dated, Tabarrok (2000) details the extent of off-label prescribing in the U.S. as follows: According to a study by the U.S. General Accounting Office, 56 percent of cancer patients have been given non-FDA-approved prescriptions, and 33 percent…